'Case-by-case' approach to GPs prescribing budesonide for COVID-19

Inhaled budesonide is not expected to be routinely prescribed for patients receiving treatment in the community for COVID-19 but can be considered 'case-by-case' by GPs, NHS officials have said.

An update issued through the NHS central alerting system on 12 April said that 'inhaled budesonide is not currently being recommended as standard of care but can be considered (off-label) on a case-by-case basis for symptomatic COVID-19 positive patients aged 65 and over, or aged 50 or over with co-morbidities'.

Advice issued from NHS leaders comes after a groundbreaking GP-led trial reported this week that the common corticosteroid could significantly reduce recovery time in patients with COVID-19 receiving treatment in the community.

Patients treated with the asthma drug were also less likely to require hospitalisation - although findings from the PRINCIPLE trial said numbers were too small to draw firm conclusions on whether budesonide could reduce risk of hospitalisation.

COVID-19 treatment

An interim position statement backed by UK health authorities says patients are eligible to be considered for treatment with inhaled budesonide if all of the following criteria are met:

  • Patients with onset of symptoms of COVID-19 within the past 14 days and symptoms are ongoing,
  • COVID-19 confirmed by PCR test within the past 14 days,
  • 65 years and over OR 50-64 years with a comorbidity consistent with a long-term health condition from the flu list.

The position statement also sets out advice on doses and products that can be prescribed - and highlights that advice on used of inhaled budesonide could be updated based on further results from the PRINCIPLE trial, as well as from further studies.

The therapeutic alert published by the NHS says prescribers should 'consider prescribing inhaled budesonide (off-label, on a case-by-case basis) for symptomatic COVID-19 positive patients in line with the published interim position statement using the usual routes, where supply allows'.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Under 40s to be offered alternative to AstraZeneca COVID-19 vaccine

Under 40s to be offered alternative to AstraZeneca COVID-19 vaccine

Patients aged 30-39 will be offered an alternative to the Oxford/AstraZeneca COVID-19...

GPs per patient down 10% in just five years, NHS data reveal

GPs per patient down 10% in just five years, NHS data reveal

The number of fully-qualified, full-time equivalent (FTE) GPs per patient in England...

Supportive model must replace harmful CQC inspections, BMA chair warns

Supportive model must replace harmful CQC inspections, BMA chair warns

CQC inspections that ‘divert time away from patient care’ and ‘instil fear’ among...

UK COVID-19 vaccination programme tracker

UK COVID-19 vaccination programme tracker

GPs across the UK are playing a leading role in the largest-ever NHS vaccination...

A 'tsunami' of work is drowning general practice: GPs speak out about a profession at its limit

A 'tsunami' of work is drowning general practice: GPs speak out about a profession at its limit

Rocketing workloads created by huge backlogs of cases and continuing COVID-19 disruption...

Slight increase in GP workforce during past year, but number of partners continues to fall

Slight increase in GP workforce during past year, but number of partners continues to fall

The GP workforce grew by 0.4% in the year to March 2021, but the number of GP partners...